Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Inclusion Criteria: * Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer that is platinum resistant. * Have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal * Greater than or equal to 18 years of age * Have clinically acceptable laboratory screening results * Have an ECOG performance status of 0 or 1 * Able to tolerate oral medications Exclusion Criteria: * Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); require two or more antihypertensive medications to control hypertension (including ACE inhibitors, beta blockers, calcium channel blockers, or diuretics) * Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec * Have active, acute, or chronic clinically significant infections or bleeding * Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome